Nov 22, 2021 — 4 min read
Studies include external validation from multiple clinical sites such as Sweden Karolinska Institute, Korea’s Seoul National University Hospital, and Netherlands Radboud University Hospital
Highlighted abstracts show the diagnostic value of Lunit AI to improve the accuracy of radiologists detecting key diseases--oral presentations during the event is to be made
Lunit, a leading medical AI provider, announced that there will be 13 abstracts presented at this year’s RSNA, demonstrating its AI solutions for radiology through internally conducted studies as well as clinical studies from external radiologists. The number is likely to be one of the most by any company in the industry, according to Lunit.
Among the 13 abstracts, three are on Lunit’s newly developed AI solution for digital breast tomosynthesis (DBT), which is the three-dimensional version of the conventional two-dimensional mammography test, rapidly becoming the main screening modality for breast cancer. In the highlight abstract selected to be presented orally, Lunit INSIGHT DBT was demonstrated to have very high accuracy, with an area under the curve (AUC) of 0.943 and sensitivity and specificity of 84.5% and 91.6%, respectively.
“This is the first time to showcase Lunit INSIGHT DBT in RSNA and we are glad to present meaningful results as the official launch is on its way,” said Ki Hwan Kim, Chief Medical Officer of Lunit. “Through many years of internal validation, we believe the AI algorithm using a large dataset of DBT can improve breast cancer detection and has the potential to show consistent performance across different patient populations and mammography vendors.”
Five abstracts to be presented focus on Lunit’s AI solution for mammography, Lunit INSIGHT MMG, an FDA cleared product for breast cancer detection. All five abstracts are external validation studies from multiple sites that highlight the value created by the use of Lunit INSIGHT MMG in clinical practice, including a study conducted in Sweden’s Karolinska Institute. The study demonstrated Lunit INSIGHT MMG to have a lower false-negative rate of 1.1 cases per 1,000 compared to radiologists having a false negative rate of 1.4 cases per 1,000 among a large dataset of 113,120 screening examinations.
Kim added, “the findings from the study support that AI can have an important complementary role when combined with radiologists, especially to increase sensitivity for high-density women.”
An additional five abstracts on Lunit’s AI solution for chest x-ray, Lunit INSIGHT CXR, will also be presented, among which four studies were results from actual clinical use in multiple sites. In a study selected for oral presentation conducted in Korea’s Seoul National University Hospital, when Lunit INSIGHT CXR was used in actual clinical practice by radiologists, particularly for patients who received percutaneous transthoracic needle biopsy, the sensitivity to detect pneumothorax was shown to be 85.4%, which was significantly superior to the 67.1% sensitivity when it was not used.
In another study conducted in Netherlands Radboud University Hospital, Lunit INSIGHT CXR was shown to be superior to eight radiologists in detecting lung nodules with an AUC value of 0.93 compared to 0.82.
“We have been demonstrating the significant value our AI technology provides through numerous studies for many years,” said Brandon Suh, CEO of Lunit. “Marking the sixth time at RSNA, we are glad to further add evidence from actual clinical practice that AI can significantly augment the capability of radiologists to accurately diagnose key diseases.”
All the series of Lunit INSIGHT products will be showcased at RSNA Lunit booth #4545. Some of the products will be available for demonstration not only at Lunit booth, but also displayed at our global partners’ booths: FUJIFILM, GE Healthcare, Philips, INFINITT healthcare, and SECTRA.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Uncertainty and Deep Learning
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do medical studies say about AI for COVID-19 management?
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI
Fujifilm Introduces its AI-powered Product for Chest X-ray in Japan, in Collaboration with Lunit
Lunit Collaborates with Intel to Provide AI Solutions to CPU-Based Customers in Need of Effective X-ray Diagnosis
Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021
Case of the Month (Chest x-ray)
COVID Global User Testimonials
Where is Cancer?
Breast Cancer Awareness Month — Ambassador Messages
TimeSformer: Is Space-Time Attention All You Need for Video Understanding?
Evaluation curves for object detection algorithms in medical images
Lunit to Participate in RSNA 2021, Presenting its New AI Solutions for Digital Breast Tomosynthesis and Chest CT
RadLink, Singapore’s Leading Imaging Center, Adapts Lunit AI to Analyze Chest X-rays and Mammograms
Lunit Expands Team with Multiple Industry Leaders to Accelerate its Business Growth
Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting
Lunit Gets FDA Nod for AI-based Chest X-ray Triage Solution, Developed for Sorting of Emergency Cases
Lunit's AI Software for Breast Cancer Detection, Lunit INSIGHT MMG, Wins FDA Clearance
Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare Investors